Investigating a new treatment target for uterine fibroids
Official title: The STAT3 Pathway in Uterine Leiomyoma: A Therapeutic Target
Funded at Northwestern University at Chicago · NIH-11072256 · Data updated 2026-11-12
This study is looking at how certain genetic changes, especially one called the MED12 mutation, help fibroids grow, with the hope of finding new, less invasive treatments that could help people with these tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $681,337 |
| NIH project number | 1R01CA298456-01 |
| Project ID | NIH-11072256 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with uterine leiomyomas, particularly those with the MED12 mutation.
✕Less likely to help
Patients without uterine leiomyomas or those with fibroids not associated with the MED12 mutation may not benefit from this research.
What this research studies
This research focuses on understanding the role of the STAT3 pathway in the growth of uterine leiomyomas, commonly known as fibroids. By exploring the genetic mutations that lead to these tumors, particularly the MED12 mutation, the study aims to identify new therapeutic strategies. The approach involves examining how these mutations affect cellular processes and the potential for targeted treatments that could inhibit tumor growth. Patients may benefit from insights that could lead to non-invasive treatment options for fibroids.
Why it matters
Potential benefit: If successful, this research could lead to new, effective non-invasive treatments for uterine fibroids.
How similar studies have gone: Previous research has shown promise in targeting genetic mutations in tumors, suggesting that this approach could be effective.
Where this research is happening
-
Northwestern University at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Bulun, Serdar E. — Northwestern University at Chicago
- Study coordinator: Bulun, Serdar E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.